Related references
Note: Only part of the references are listed.HPF1 remodels the active site of PARP1 to enable the serine ADP-ribosylation of histones
Fa-Hui Sun et al.
NATURE COMMUNICATIONS (2021)
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
Johannes Rudolph et al.
NATURE COMMUNICATIONS (2021)
Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity
Travis Eisemann et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Jennifer Taylor Veneris et al.
GYNECOLOGIC ONCOLOGY (2020)
Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Zsofia Sztupinszki et al.
CLINICAL CANCER RESEARCH (2020)
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Heng Zhu et al.
MOLECULAR CANCER (2020)
HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation
Marcin J. Suskiewicz et al.
NATURE (2020)
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
Simonetta Pazzaglia et al.
CELLS (2020)
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al.
SCIENCE (2020)
AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization
Jacob O. Spiegel et al.
JOURNAL OF CHEMINFORMATICS (2020)
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd et al.
ONCOGENE (2020)
Bridging of DNA breaks activates PARP2-HPF1 to modify chromatin
Silvija Bilokapic et al.
NATURE (2020)
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
Zhengping Shao et al.
NUCLEIC ACIDS RESEARCH (2020)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation
Juan Jose Bonfiglio et al.
CELL (2020)
Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins
Elizaveta E. Alemasova et al.
NUCLEIC ACIDS RESEARCH (2019)
Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity
Uday Kiran Velagapudi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Hit and run versus long-term activation of PARP-1 by its different domains fine-tunes nuclear processes
Colin Thomas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Eukaryotic Base Excision Repair: New Approaches Shine Light on Mechanism
William A. Beard et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
Mammalian DNA Polymerase Kappa Activity and Specificity
Hannah R. Stern et al.
MOLECULES (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
BlendMol: advanced macromolecular visualization in Blender
Jacob D. Durrant
BIOINFORMATICS (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers
Tatiana Kamaletdinova et al.
CELLS (2019)
Advances and perspectives of PARP inhibitors
Ming Yi et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
Helene Marijon et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
PARP Inhibitors in Breast Cancer: Bringing Synthetic Lethality to the Bedside
Anita A. Turk et al.
CANCER (2018)
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola et al.
CANCER CELL (2018)
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Gwynn Ison et al.
CLINICAL CANCER RESEARCH (2018)
Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors
Xuxing Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Homologous recombination and the repair of DNA double-strand breaks
William Douglass Wright et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
Hana Hanzlikova et al.
MOLECULAR CELL (2018)
NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains
Marie-France Langelier et al.
NATURE COMMUNICATIONS (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Serine is the major residue for ADP-ribosylation upon DNA damage
Luca Palazzo et al.
ELIFE (2018)
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Emanuel Nicolas et al.
CANCERS (2018)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Mechanisms of DNA Damage, Repair, and Mutagenesis
Nimrat Chatterjee et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2017)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Stephanie A. Yazinski et al.
GENES & DEVELOPMENT (2017)
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Benjamin G. Bitler et al.
GYNECOLOGIC ONCOLOGY (2017)
Non-homologous DNA end joining and alternative pathways to double-strand break repair
Howard H. Y. Chang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1
Lili Liu et al.
NUCLEIC ACIDS RESEARCH (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock J. Sishc et al.
CANCERS (2017)
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer
Sanjeeve Balasubramaniam et al.
CLINICAL CANCER RESEARCH (2017)
HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
Ian Gibbs-Seymour et al.
MOLECULAR CELL (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du et al.
NATURE MEDICINE (2016)
Functions of PARylation in DNA Damage Repair Pathways
Huiting Wei et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2016)
BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy
Sadako Akashi-Tanaka et al.
CLINICAL BREAST CANCER (2015)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs
Jean-Philippe Gagne et al.
DNA REPAIR (2015)
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Gianluca Papeo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Mechanistic Dissection of PARP1 Trapping and the Impacton In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2015)
Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation
Eva Barkauskaite et al.
MOLECULAR CELL (2015)
The Promise of Proteomics for the Study of ADP-Ribosylation
Florian J. Bock et al.
MOLECULAR CELL (2015)
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
Sebastian Eustermann et al.
MOLECULAR CELL (2015)
PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
Jennine M. Dawicki-McKenna et al.
MOLECULAR CELL (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian
Jacqueline Mersch et al.
CANCER (2015)
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
Selvi Durmus et al.
PHARMACEUTICAL RESEARCH (2015)
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Conformational Activation of Poly(ADP-ribose) Polymerase-1 upon DNA Binding Revealed by Small-Angle X-ray Scattering
Steven O. Mansoorabadi et al.
BIOCHEMISTRY (2014)
Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer
Jamin D. Steffen et al.
CANCER RESEARCH (2014)
Distribution of protein poly(ADP-ribosyl)ation systems across all domains of life
Dragutin Perina et al.
DNA REPAIR (2014)
POVME 2.0: An Enhanced Tool for Determining Pocket Shape and Volume Characteristics
Jacob D. Durrant et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2014)
Discovery and Structure-Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors
Maulik R. Patel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Phosphoproteomic Approach to Characterize Protein Mono- and Poly(ADP-ribosyl)ation Sites from Cells
Casey M. Daniels et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Julie K. Horton et al.
MOLECULAR CANCER RESEARCH (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Family-wide analysis of poly(ADP-ribose) polymerase activity
Sejal Vyas et al.
NATURE COMMUNICATIONS (2014)
Structure-Based Druggability Assessment of the Mammalian Structural Proteome with Inclusion of Light Protein Flexibility
Kathryn A. Loving et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Taofeek K. Owonikoko et al.
CANCER MEDICINE (2014)
BRCAness: a deeper insight into basal-like breast tumors
S. De Summa et al.
ANNALS OF ONCOLOGY (2013)
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Marie-France Langelier et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2013)
Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease
Reza Sharifi et al.
EMBO JOURNAL (2013)
Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors
Na Ye et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Mapping PARP-1 Auto-ADP-ribosylation Sites by Liquid Chromatography-Tandem Mass Spectrometry
John D. Chapman et al.
JOURNAL OF PROTEOME RESEARCH (2013)
Proteome-wide Identification of Poly(ADP-Ribosyl)ation Targets in Different Genotoxic Stress Responses
Stephanie Jungmichel et al.
MOLECULAR CELL (2013)
Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome
Yajie Zhang et al.
NATURE METHODS (2013)
Okazaki Fragment Metabolism
Lata Balakrishnan et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Repair of Double-Strand Breaks by End Joining
Kishore K. Chiruvella et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Resistance to PARP-inhibitors in cancer therapy
Alicia Montoni et al.
FRONTIERS IN PHARMACOLOGY (2013)
Structural implications for selective targeting of PARPs
Jamin D. Steffen et al.
FRONTIERS IN ONCOLOGY (2013)
DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment
Andrea Volkamer et al.
BIOINFORMATICS (2012)
A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
Katharina Schlacher et al.
CANCER CELL (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Lenka Oplustilova et al.
CELL CYCLE (2012)
Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly (ADP-ribosyl)ation-dependent ubiquitination
Zhizhi Wang et al.
GENES & DEVELOPMENT (2012)
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
Xin Luo et al.
GENES & DEVELOPMENT (2012)
Structure of mammalian poly(ADP- ribose) glycohydrolase reveals a flexible tyrosine clasp as a substrate-binding element
In-Kwon Kim et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
FTMAP: extended protein mapping with user-selected probe molecules
Chi Ho Ngan et al.
NUCLEIC ACIDS RESEARCH (2012)
Pleiotropic Cellular Functions of PARP1 in Longevity and Aging: Genome Maintenance Meets Inflammation
Aswin Mangerich et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2012)
Hyperactivation of PARP Triggers Nonhomologous End-Joining in Repair-Deficient Mouse Fibroblasts
Natalie R. Gassman et al.
PLOS ONE (2012)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
Functional Aspects of PARP1 in DNA Repair and Transcription
Hui Ling Ko et al.
BIOMOLECULES (2012)
The role of PARP in DNA repair and its therapeutic exploitation
M. Javle et al.
BRITISH JOURNAL OF CANCER (2011)
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Sebastian M. B. Nijman
FEBS LETTERS (2011)
Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DNA-DEPENDENT PARP-1 ACTIVITY
Marie-France Langelier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Patryk Moskwa et al.
MOLECULAR CELL (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase
Dea Slade et al.
NATURE (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
Amal Aly et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2011)
Overview of Base Excision Repair Biochemistry
Yun-Jeong Kim et al.
Current Molecular Pharmacology (2011)
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
Ponnari Gottipati et al.
CANCER RESEARCH (2010)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction
Marie-France Langelier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Dana V. Ferraris
JOURNAL OF MEDICINAL CHEMISTRY (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Parthanatos, a messenger of death
Karen Kate David et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Identification of the ADP-Ribosylation Sites in the PARP-1 Automodification Domain: Analysis and Implications
Zhihua Tao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Xuesong Liu et al.
MOLECULAR CANCER RESEARCH (2009)
Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites
Matthias Altmeyer et al.
NUCLEIC ACIDS RESEARCH (2009)
Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells
Muraildhar L. Hegde et al.
CELL RESEARCH (2008)
Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through the BRCA2 Promoter
Jinhua Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins
Ivan Ahel et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Single-strand break repair and genetic disease
Keith W. Caldecott
NATURE REVIEWS GENETICS (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation
Marie-France Langelier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors
Richard W. Martin et al.
CANCER RESEARCH (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
Opinion -: Invasive growth:: a MET-driven genetic programme for cancer and stem cells
Carla Boccaccio et al.
NATURE REVIEWS CANCER (2006)
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution
CX Deng
NUCLEIC ACIDS RESEARCH (2006)
ProRule: a new database containing functional and structural information on PROSITE profiles
CJA Sigrist et al.
BIOINFORMATICS (2005)
Specificity of protein interactions mediated by BRCT domains of the XRCC1 DNA repair protein
PT Beernink et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase
T Kinoshita et al.
FEBS LETTERS (2004)
Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase
K Hattori et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins
JM Pleschke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
